肥胖与脊柱关节炎临床表现及疾病负担的关联:ASAS-PerSpA辅助研究
该研究基于ASAS-PerSpA横断面研究24国4449例脊柱关节炎患者,按当前BMI及20岁时BMI分组,比较肥胖与临床表现及疾病负担的关系。结果显示肥胖/超重患者生物制剂使用负担更高、疗效不佳更常见、工作能力受损更重且患者报告健康状况更差,校正年龄、性别和吸烟后差异仍存在。
要点
- 肥胖/超重SpA患者生物制剂使用种类更多、停药更多且疗效不佳更常见。
- 肥胖/超重SpA患者工作能力受损更重,患者报告健康状况更差。
- 按20岁时BMI分组比较也发现类似差异,提示早年肥胖同样相关。
核心结论
- 肥胖与SpA患者生物制剂 burden、工作生产力损失及更差的患者报告健康状况相关。
研究设计与样本
- ASAS-PerSpA横断面研究的辅助分析,纳入24个参与国的4449例脊柱关节炎患者。
主要发现
- 4449例患者中34.6%超重、21%肥胖、44.4%正常体重。
- 肥胖/超重患者btDMARD负担更高、btDMARD疗效不佳、工作能力受损及患者报告健康更差(p均<0.05)。
- 校正年龄、性别和吸烟后上述差异仍存在,按20岁时BMI分组比较也发现类似差异。
临床怎么用
- 对SpA患者应关注体重状态,肥胖/超重可能提示更高的生物制剂使用负担和更差的工作与健康状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aims to explore the relationship of obesity with clinical manifestations and disease burden including biologic/targeted DMARD (btDMARD), SpA-related surgery, work productivity loss, and patient-reported health status. METHODS: An ancillary analysis of the Assessment of Spondyloarthritis International Society PerSpA (PERipheral involvement in SpA) cross-sectional study from 24 participating countries. The PerSpA study included the data of clinical characteristics, btDMARD use and history (number of btDMARD kinds ever-prescribed, number of discontinuation, and the reasons for discontinuation), SpA-related surgery, work productivity and activity impairment, and patient-reported health status (ASAS Health Index, Bath Ankylosing Spondylitis Functional Index, and global wellbeing). Patients were divided into three groups according to the current BMI (BMIc) and comparisons between the obese patients, overweights, and normal weights were performed for the above-mentioned parameters. The study population was also divided into different three groups according to their 20-year-old BMI (BMI20y) and they were compared in itself. RESULTS: Among the 4449 patients, 34.6% were overweight, 21% obese, and 44.4% normal-weight. Obese/overweight patients had a higher btDMARD burden, btDMARD inefficacy, work impairment, and worse patient-reported health (p < 0.05 for all). The differences were preserved in comparisons adjusted for age, gender, and smoking. When the patients were compared according to their BMI20y, similar differences were also found. CONCLUSIONS: Obesity invites a biological therapy burden, work productivity loss, and worse patient-reported health status in patients with SpA.
引用
- Duruöz MT, Acer Kasman S, Gezer HH, et al. Obesity and its associations with clinical manifestations and disease burden of patients with spondyloarthritis: An ancillary study from the ASAS-PerSpA project. Semin Arthritis Rheum. 2025. PMID: 41513543. doi:10.1016/j.semarthrit.2025.152904
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。